Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does UPADACITINIB Cause Systemic inflammatory response syndrome? 16 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 16 reports of Systemic inflammatory response syndrome have been filed in association with UPADACITINIB (Rinvoq). This represents 0.0% of all adverse event reports for UPADACITINIB.

16
Reports of Systemic inflammatory response syndrome with UPADACITINIB
0.0%
of all UPADACITINIB reports
0
Deaths
2
Hospitalizations

How Dangerous Is Systemic inflammatory response syndrome From UPADACITINIB?

Of the 16 reports, 2 (12.5%) required hospitalization, and 1 (6.3%) were considered life-threatening.

Is Systemic inflammatory response syndrome Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for UPADACITINIB. However, 16 reports have been filed with the FAERS database.

What Other Side Effects Does UPADACITINIB Cause?

Pain (4,444) Arthralgia (3,815) Drug ineffective (3,384) Covid-19 (2,978) Rheumatoid arthritis (2,730) Pain in extremity (2,353) Fatigue (2,153) Fall (2,081) Surgery (2,037) Therapy interrupted (1,741)

What Other Drugs Cause Systemic inflammatory response syndrome?

DOXORUBICIN (161) METHOTREXATE (158) CYCLOPHOSPHAMIDE (153) CYTARABINE (153) METHYLPREDNISOLONE (117) ADALIMUMAB (107) RITUXIMAB (106) PREDNISOLONE (99) VINCRISTINE (97) MYCOPHENOLATE MOFETIL (95)

Which UPADACITINIB Alternatives Have Lower Systemic inflammatory response syndrome Risk?

UPADACITINIB vs URAPIDIL UPADACITINIB vs UREA UPADACITINIB vs URIDINE TRIACETATE UPADACITINIB vs UROFOLLITROPIN UPADACITINIB vs URSODIOL

Related Pages

UPADACITINIB Full Profile All Systemic inflammatory response syndrome Reports All Drugs Causing Systemic inflammatory response syndrome UPADACITINIB Demographics